<DOC>
	<DOCNO>NCT00093353</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan temozolomide , work different way stop tumor cell divide stop grow die . Temozolomide may help irinotecan kill tumor cell make sensitive drug . Cefixime may effective prevent diarrhea cause treatment irinotecan . PURPOSE : This phase I trial study side effect best dose irinotecan give together temozolomide cefixime treat young patient recurrent resistant neuroblastoma .</brief_summary>
	<brief_title>N2003-01 : Irinotecan , Temozolomide , Cefixime Treating Young Patients With Recurrent Resistant Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose oral irinotecan administer fixed-dose temozolomide cefixime pediatric patient recurrent resistant high-risk neuroblastoma . - Determine toxic effect regimen patient . Secondary - Determine response rate patient treat regimen . - Determine pharmacokinetics regimen patient . - Correlate UGT1A1 genotype occurrence dose-limiting diarrhea patient treat regimen . - Correlate BCRP genotype pharmacokinetic phenotype patient treat regimen . - Correlate p53 status tumor cell response patient treat regimen . OUTLINE : This multicenter , dose-escalation study irinotecan . Patients receive oral cefixime daily begin 5 day start fixed-dose temozolomide irinotecan continue duration study . Patients also receive oral temozolomide daily day 1-5 oral irinotecan daily day 1-5 8-12 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A maximum 12 patient treated MTD . Patients follow toxicity , response , survival . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 1.25 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Cefixime</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm neuroblastoma AND/OR demonstration tumor cell bone marrow increase urinary catecholamine Highrisk disease meet 1 follow criterion : Recurrent progressive disease Resistant refractory disease ( i.e. , never achieve complete response therapy AND never new site disease progression initial site ) Measurable disease meeting least 1 follow criterion : Unidimensionally measurable tumor ≥ 20 mm MRI , CT scan , xray OR ≥ 10 mm spiral CT scan* At least 1 site positive uptake metaiodobenzylguanidine ( MIBG ) scan* Bone marrow tumor cell see routine morphology ( NSE stain ) bilateral aspirate AND/OR biopsy 1 bone marrow sample NOTE : *Patients never experience disease recurrence progression must demonstrate viable neuroblastoma biopsy either bone marrow bone and/or soft tissue site ( biopsy must perform ≥ 4 week completion prior radiotherapy lesion irradiate ) PATIENT CHARACTERISTICS : Age 1 30 diagnosis Performance status ECOG 02 Life expectancy At least 2 month Hematopoietic Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 75,000/mm^3 ( without transfusion ) Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Hepatic SGPT SGOT &lt; 5 time normal Bilirubin ≤ 1.5 time normal Renal Creatinine ≤ 1.5 time normal age No great 0.8 mg/dL ( ≤ 5 year age ) No great 1.0 mg/dL ( 6 10 year age ) No great 1.2 mg/dL ( 11 15 year age ) No great 1.5 mg/dL ( &gt; 15 year age ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy cephalosporins No active diarrhea No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy Recovered prior immunotherapy More 3 week since prior biologic therapy recover More 2 day since prior hematopoietic growth factor No concurrent epoetin alfa No concurrent prophylactic hematopoietic growth factor first treatment course No concurrent immunomodulating agent except steroid control intracranial pressure Chemotherapy Prior myeloablative therapy autologous stem cell transplantation allow No prior allogeneic stem cell transplantation More 3 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover Prior temozolomide , irinotecan , topotecan allow No prior temozolomide irinotecan combination therapy No concurrent chemotherapy Endocrine therapy See Biologic therapy Radiotherapy At least 6 week since prior large field radiotherapy ( e.g. , total body irradiation , craniospinal therapy , whole abdomen , total lung , &gt; 50 % bone marrow space ) recover At least 4 week since prior radiotherapy biopsied lesion ( study entry ) recover At least 6 week since prior MIBG therapy Concurrent radiotherapy painful lesion allow provided lesion use assess treatment response Surgery Not specify Other No concurrent enzymeinducing anticonvulsant ( e.g. , phenobarbital , phenytoin , carbamazepine ) No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>diarrhea</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>